You are viewing: US Clinical Trial Imaging Market analysis
Part of: Clinical Trial Imaging Market (Global)

The US Clinical Trial Imaging Market was valued at $472.89 Million in 2024 and projected to reach to $734.74 Million by 2029, representing a compound annual growth rate of 9.2%. The US clinical trial imaging market is positioned for sustained growth through 2029, driven by increasing pharmaceutical R&D spending, FDA modernization initiatives, and the adoption of AI-powered imaging analytics.

US Clinical Trial Imaging Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Clinical Trial Imaging Market Trends and Insights

  • This expansion reflects the US healthcare sector's increasing reliance on advanced imaging technologies to accelerate drug development and regulatory approval processes.
  • The US market benefits from substantial R&D investments, a mature pharmaceutical ecosystem, and stringent regulatory standards that drive demand for high-quality imaging solutions in clinical trials. Driving this growth, the US is witnessing heightened adoption of AI-powered imaging analytics, real-time monitoring capabilities, and integrated imaging platforms across Phase I through Phase IV trials.
  • The US regulatory environment, particularly FDA guidance on imaging biomarkers, continues to incentivize sponsors and contract research organizations (CROs) to invest in sophisticated imaging infrastructure.
  • Between 2024 and 2029, the US market's 9.2% compound annual growth rate significantly outpaces global trends, positioning the country as a critical hub for clinical trial imaging innovation and deployment..

Key Market Statistics

  • CAGR (2024-2029) 9.2% CAGR
  • Market Size, 2024 ~USD 472.89 Million
  • Forecast, 2029 ~USD 734.74 Million
  • Country US

US Clinical Trial Imaging Market Overview

Market Valuation Growth :

The US clinical trial imaging market is valued at $472.89 million in 2024, with a strong CAGR of 9.2%, significantly outpacing the global growth rate of 7.8%, demonstrating the US market's accelerated expansion.

Forecast Expansion :

The market is projected to reach $734.74 million by 2029, representing a 55.3% increase over five years, driven by increased adoption of advanced imaging technologies in pharmaceutical development and regulatory processes.

R&D Investment Leadership :

The US pharmaceutical and biotech sectors maintain substantial R&D investments, creating a robust ecosystem for clinical trial imaging adoption and innovation in drug development acceleration.

Regulatory Approval Acceleration :

Advanced imaging technologies in US clinical trials enable faster regulatory approval processes, reducing time-to-market for new therapeutics and enhancing competitive advantage for pharmaceutical companies.

US Clinical Trial Imaging Market Dynamics

  • The mature US healthcare infrastructure and regulatory framework support rapid technology integration, while growing demand for precision medicine and personalized therapeutics accelerates imaging utilization in clinical trials. Key growth drivers include the expansion of oncology and neurology trials requiring advanced imaging, increased outsourcing to contract research organizations (CROs), and integration of real-time imaging data analytics.
  • The US market's premium positioning reflects higher technology adoption rates and reimbursement capabilities compared to global peers, ensuring continued investment in next-generation imaging solutions..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Diagnostic Imaging

      Top Technologies
      • Magnetic Resonance Imaging (MRI)
      • Computed Tomography (CT)
      • CT Scanners
      • Nuclear Imaging
      • Positron Emission Tomography
      Top Companies
      • Siemens healthineers
      • PHILIPS HEALTHCARE
      • CANON INC.
      • FUJIFILM Holdings Corporation
      • UNITED IMAGING HEALTHCARE CO., LTD.

        Key Takeaways

        • The US clinical trial imaging market is valued at $472.89 million in 2024 and is forecast to reach $734.74 million by 2029, representing a 9.2% CAGR.
        • The US market growth is driven by FDA regulatory emphasis on imaging biomarkers and increased adoption of AI-powered imaging analytics in clinical trials.
        • The US pharmaceutical and CRO sectors are investing heavily in advanced imaging infrastructure to accelerate drug development timelines and improve trial outcomes.
        • The US market's 9.2% CAGR outpaces the global average of 7.8%, reflecting the country's leadership in clinical trial innovation and imaging technology deployment.

        Clinical Trial Imaging Market Report Scope

        Report Metric Details
        Base Year 2024
        Fastest Growing Segment ONCOLOGY (Therapeutic Area)
        Forecast Period 2024–2029
        Growth Rate CAGR of 7.8% from 2024 to 2029
        Largest Segment SERVICES (Service & Software)
        Market Size Base Year (Billions) ~USD 1.42 (2024)
        Revenue Forecast (Billions) ~USD 2.07 (2029)
        Segments Covered Service & Software, Type, Modality, Therapeutic Area, End User

        US Clinical Trial Imaging Market Report Segmentation

        5 segment dimensions are covered across the global market.

        By Service & Software

        • Services
        • Software

        By Type

        • Operational Imaging Services
        • Read Analysis Services
        • System And Technical Support Services
        • Trial Design And Consulting Services
        • Trial Design Consulting Services

        By Modality

        • Computed Tomography
        • Magnetic Resonance Imaging
        • Other Modalities
        • Positron Emission Tomography
        • Ultrasound
        • X-Ray

        By Therapeutic Area

        • Cardiovascular System Disorders
        • Endocrinology
        • Immunological Disorders
        • Infectious Diseases
        • Neurology
        • Oncology
        • Other Therapeutic Areas

        By End User

        • Academic And Government Research Institutes
        • Contract Research Organizations
        • Medical Device Manufacturers
        • Other End Users
        • Pharmaceutical & Biotechnology Companies

        US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029

        Segment20222023202420252026202720282029CAGR (%)
        ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES13.9714.7415.7316.8117.9919.2720.6722.217.1
        CONTRACT RESEARCH ORGANIZATIONS4445.3148.6552.356.360.6965.570.797.8
        MEDICAL DEVICE MANUFACTURERS66.7774.7980.6387.0394.07101.8110.32119.718.2
        OTHER END USERS10.3512.0112.7713.5914.4815.4516.517.666.7
        PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES382.5399.09433.72471.94514.17560.93612.72670.119.1
        TOTAL517.59545.94591.5641.67697.01758.14825.71900.488.8

        Target Audience

        • Pharmaceutical & Biotech Companies : Need US market insights to optimize clinical trial imaging investments, accelerate drug development timelines, and understand competitive imaging technology adoption rates among peers.
        • Medical Imaging Device Manufacturers : Require detailed US market data to identify growth opportunities, develop targeted product roadmaps for clinical trial applications, and benchmark against competitors in the high-growth segment.
        • Contract Research Organizations (CROs) : Depend on US market forecasts to plan imaging service expansion, invest in technology infrastructure, and position imaging capabilities as competitive differentiators for clinical trial contracts.
        • Healthcare Investors & Private Equity : Seek comprehensive US market analysis to evaluate investment opportunities in imaging technology companies, assess portfolio company growth potential, and identify acquisition targets in clinical trials.
        • Healthcare Consultants & Analysts : Utilize US-specific market data to support client strategy development, competitive analysis, and market entry planning for imaging solution providers and healthcare technology firms.

        Key Companies in the US Clinical Trial Imaging Market

        CompanyHQOwnershipStrongest segments
        PATHEON INCNetherlandsPrivate CompanyDrug product services (finished dosage manufacturing, packaging, lifecycle),Pharmaceutical development services (formulation, analytical, clinical supply),Drug substance services (small- and large-molecule APIs),
        BIOMERIEUX S.A.FrancePublic CompanyClinical microbiology (VITEK, culture media, BACT/ALERT, ETEST, API),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA),
        TAKE SOLUTIONSIndiaPublic CompanyClinical research and data sciences,Pharmacovigilance, safety, and regulatory affairs,Generics development services,
        BRUKER CORPORATIONUnited StatesPublic CompanyBSI BioSpin (NMR, EPR, preclinical imaging),BSI CALID (mass spectrometry, molecular diagnostics, automation),BSI Nano (X-ray, AFM, electron microscopy tools),
        SANOFIFrancePublic CompanyVaccines (pediatric, RSV, hexavalent, travel),Immunology & Inflammation,Rare Diseases & Neurology,
        MEDIDATA SOLUTIONSUnited StatesPrivate CompanyCore clinical data capture and management (EDC, CTMS, monitoring),Decentralized trial and patient engagement solutions,Data analytics and insights offerings,
        ZENSAR TECHNOLOGIES LTDIndiaPublic CompanyDigital and Application Services,Cloud Infrastructure and Security Services,Brand, Marketing, and Consulting Services,
        TENET HEALTHCARE CORPORATIONUnited StatesPublic CompanyHospital Operations and Services,Ambulatory Care (ASCs and Surgical Hospitals),Other Outpatient and Ancillary Services,
        UNITED IMAGING HEALTHCARE CO., LTD.ChinaPublic CompanyMagnetic Resonance Imaging,Computed Tomography,Molecular Imaging (PET/CT, SPECT),
        ICON PLCIrelandPublic CompanyClinical development services (Phase I–IV, peri/post-approval),Functional service partnerships & contract staffing,Laboratory and testing services (bioanalytical, biomarker, central labs, vaccine, GMP),
        MEDPACEUnited StatesPublic CompanyFull-service clinical development (Phase I–IV),Central and bio-analytical laboratory services,Specialized services (imaging, ECG, human pharmacology),
        IXICO PLCUnited KingdomPublic CompanyImaging CRO services (biomarkers, reads, trial management),AI-enabled IXICO platform and data analytics,Post-marketing surveillance, clinical diagnostics, and consultancy,
        RESONANCE HEALTH LTD.AustraliaPublic CompanyFerriScan and CardiacT2 LIC/iron-loading services,AI SaMD (FerriSmart, HepaFatSmart, LiverSmart),HepaFatScan and related liver-fat MRI services,
        WCG CLINICALUnited StatesPrivate CompanyRegulatory and ethical review / human research protections,Technology platforms (eConsent, AIMS, Velos eResearch eXpress),Consulting, biosafety, and online learning,

        PATHEON INC

        Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and life sciences sector.

        BIOMERIEUX S.A.

        bioMérieux S.A. is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics and microbiology testing solutions.

        TAKE SOLUTIONS

        Take Solutions is an India-based public company founded in 2000 with 2 employees providing business and technology services.

        BRUKER CORPORATION

        Bruker Corporation is a United States-based public company founded in 1960 with 11,085 employees manufacturing scientific instruments and analytical solutions.

        SANOFI

        Sanofi is a French multinational public pharmaceutical company founded in 1994 with 74,846 employees engaged in drug discovery, development, and manufacturing.

        MEDIDATA SOLUTIONS

        Medidata Solutions is a United States-based private company founded in 1999 with 1,998 employees providing cloud-based clinical trial software and services.

        ZENSAR TECHNOLOGIES LTD

        Zensar Technologies Ltd is an India-based public company founded in 1963 with 10,066 employees providing IT services and digital transformation solutions.

        TENET HEALTHCARE CORPORATION

        Tenet Healthcare Corporation is a United States-based public company founded in 1967 with 88,500 employees operating a large network of hospitals and healthcare facilities.

        UNITED IMAGING HEALTHCARE CO., LTD.

        United Imaging Healthcare Co., Ltd. is a China-based public company founded in 2011 with 8,703 employees manufacturing medical imaging equipment and healthcare solutions.

        ICON PLC

        ICON PLC is an Ireland-based public company founded in 1989 with 40,350 employees providing clinical research and drug development services.

        MEDPACE

        Medpace is a United States-based public company founded in 1992 with 6,300 employees offering clinical research and development services.

        IXICO PLC

        IXICO PLC is a United Kingdom-based public company with 79 employees specializing in medical imaging analysis and clinical trial services.

        RESONANCE HEALTH LTD.

        Resonance Health Ltd. is an Australia-based public company founded in 1987 with 16 employees providing medical imaging analysis and software solutions.

        WCG CLINICAL

        WCG Clinical is a United States-based private company founded in 1968 with 1,342 employees providing clinical research and trial management services.

        Reasons to Buy this Report

        • Market Size & Growth Validation : Obtain precise US market valuation ($472.89M in 2024) and verified CAGR of 9.2% through 2029, enabling accurate financial forecasting and investment decision-making for clinical trial imaging solutions.
        • Competitive Landscape Intelligence : Understand the US-specific competitive dynamics, key market players, and technology adoption patterns to identify market gaps and positioning opportunities for imaging vendors and service providers.
        • Regulatory & Reimbursement Insights : Access detailed analysis of US FDA requirements, reimbursement trends, and regulatory pathways specific to clinical trial imaging, critical for compliance and market entry strategies.
        • Segment & Application Analysis : Identify high-growth therapeutic areas (oncology, neurology, cardiology) and imaging modalities driving US market expansion, enabling targeted product development and marketing strategies.
        • Strategic Investment Guidance : Leverage comprehensive US market forecasts and trend analysis to guide M&A decisions, partnership strategies, and capital allocation in the clinical trial imaging sector through 2029.

        Frequently asked questions

        What is the current size of the US clinical trial imaging market?

        The US clinical trial imaging market is valued at $472.89 million in 2024 and is expected to grow to $734.74 million by 2029.

        What is the projected growth rate for the US clinical trial imaging market?

        The US clinical trial imaging market is projected to grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2029.

        What factors are driving growth in the US clinical trial imaging market?

        Key drivers include FDA regulatory guidance on imaging biomarkers, increased adoption of AI-powered imaging analytics, real-time monitoring capabilities, and substantial R&D investments by US pharmaceutical companies and CROs.

        How does the US market compare to the global clinical trial imaging market?

        The US market is growing at 9.2% CAGR, which outpaces the global average of 7.8%, demonstrating the US's leadership position in clinical trial imaging innovation and technology adoption.

        Which imaging technologies are most in demand in the US clinical trial market?

        The US market shows strong demand for AI-powered imaging analytics, integrated imaging platforms, real-time monitoring solutions, and advanced imaging biomarker technologies that support regulatory compliance and trial efficiency.

        RESEARCH METHODOLOGY

        The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the clinical trial imaging market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, market breakdown and data triangulation were used.

        The four steps involved in estimating the market size are:

        Secondary Research

        The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical trial imaging market. A database of the key industry leaders was also prepared using secondary research.

        Primary Research

        The primary research data was conducted after acquiring knowledge about the clinical trial imaging market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as hospitals & ICUs, diagnostic laboratories, research institutes, research laboratories and point-of-care settings) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

        A breakdown of the primary respondents is provided below:

        Note 1: *Others include sales managers, marketing managers, and product managers.

        Note 2: Tiers are defined based on a company’s total revenue as of 2022: Tier 1=> USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3=< USD 500 million.

        To know about the assumptions considered for the study, download the pdf brochure

        Market Size Estimation

        All major product manufacturers offering various clinical trial imaging products were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value clinical trial imaging market was also split into various segments and subsegments at the region and country level based on:

        • Product mapping of various manufacturers for each type of clinical trial imaging market at the regional and country-level  
        • Relative adoption pattern of each clinical trial imaging market among key application segments at the regional and/or country-level 
        • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country-level. 
        • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level 

        Data Triangulation

        After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the clinical trial imaging industry.

        Market Definition

        Clinical trial Imaging is used to create images during clinical trials while conducting research. Such imaging testing is mainly done using X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and positron emission tomography (PET). In clinical trials, imaging is used primarily to evaluate efficacy, endpoints, and more frequently, for safety evaluations and eligibility criteria.

        Stakeholders

        • Medical Device Industries
        • Academic and Government Research Institutes
        • Diagnostic Centers
        • Market Research & Consulting Firms
        • Clinical Trial Imaging Manufacturers, Vendors, and Distributors
        • Pharmaceutical and Biotechnology Companies and Contract Research Organizations (CROs)

        Report Objectives

        • To define, describe, segment, and forecast the clinical trial imaging market by service & software, modality, therapeutic area, end user, and region
        • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
        • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
        • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
        • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
        • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
        • To track and analyze company developments such as acquisitions, agreements, partnerships, contracts, approvals, product launches, and mergers in the clinical trial imaging market
        • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product strategy

        Get the Full Clinical Trial Imaging Market Report

        Full forecast, segment splits, and company analysis for all Clinical Trial Imaging Market.

        Need a Tailored Report?

        Customize this report to your needs

        Get 10% FREE Customization

        Customize This Report
        Fact checked
        DMCA.com Protection Status